Published in Med Microbiol Immunol on May 31, 2006
Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest (2011) 2.62
Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab (2012) 2.25
Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer (2010) 2.04
Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots. Clin Cancer Res (2011) 1.91
The effects of IL-6 on CD4 T cell responses. Clin Immunol (2008) 1.90
IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol (2009) 1.77
Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol (2012) 1.61
Cytokines in sepsis: potent immunoregulators and potential therapeutic targets--an updated view. Mediators Inflamm (2013) 1.54
Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword? FEBS J (2013) 1.33
Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression. J Immunol (2011) 1.26
Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther (2012) 1.23
Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer (2010) 1.18
Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS One (2012) 1.18
Interleukin 6 promoter polymorphisms influence the outcome of chronic hepatitis C. Immunogenetics (2010) 1.17
Cytokines as biomarkers in rheumatoid arthritis. Mediators Inflamm (2014) 1.16
Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. J Immunol (2008) 1.15
New insight into immunity and immunopathology of Rickettsial diseases. Clin Dev Immunol (2011) 1.10
Loss of Kupffer cells in diet-induced obesity is associated with increased hepatic steatosis, STAT3 signaling, and further decreases in insulin signaling. Biochim Biophys Acta (2009) 1.09
Adipose-derived Mesenchymal Stem Cells (ASCs) may favour breast cancer recurrence via HGF/c-Met signaling. Oncotarget (2014) 1.08
Mechanisms of chronic JAK-STAT3-SOCS3 signaling in obesity. JAKSTAT (2013) 1.04
Interleukin-6 and neural stem cells: more than gliogenesis. Mol Biol Cell (2008) 1.01
IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis. PLoS One (2009) 1.01
Genetic and environmental influences on systemic markers of inflammation in middle-aged male twins. Atherosclerosis (2008) 0.99
Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PLoS One (2012) 0.98
The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells. PLoS One (2011) 0.96
Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells. Arch Immunol Ther Exp (Warsz) (2008) 0.90
IL-6 regulates Mcl-1L expression through the JAK/PI3K/Akt/CREB signaling pathway in hepatocytes: implication of an anti-apoptotic role during liver regeneration. PLoS One (2013) 0.89
IL-6 downregulates transcription of NTPDase2 via specific promoter elements. Am J Physiol Gastrointest Liver Physiol (2008) 0.88
A variant near the interleukin-6 gene is associated with fat mass in Caucasian men. Int J Obes (Lond) (2010) 0.84
Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway. Int J Colorectal Dis (2010) 0.83
Soluble IL6R represents a miR-34a target: potential implications for the recently identified IL-6R/STAT3/miR-34a feed-back loop. Oncotarget (2015) 0.82
Exercise enhances vaccine-induced antigen-specific T cell responses. Vaccine (2008) 0.82
Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels. PLoS One (2013) 0.81
Gut and liver handling of interleukin-6 during liver resection in man. HPB (Oxford) (2011) 0.80
IL-6 potentiates tumor resistance to photodynamic therapy (PDT). Lasers Surg Med (2011) 0.79
Inflammation induced loss of skeletal muscle. Bone (2015) 0.79
Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update. Front Immunol (2017) 0.77
In vitro and in vivo antitumor effects of the recombinant immunotoxin IL6(T23)-PE38KDEL in multiple myeloma. Oncol Lett (2012) 0.77
IL6 to the rescue. Blood (2008) 0.77
Time-dependent effects of localized inflammation on peripheral clock gene expression in rats. PLoS One (2013) 0.77
The balance between soluble receptors regulating IL-6 trans-signaling is predictive for the RANKL/osteoprotegerin ratio in postmenopausal women with rheumatoid arthritis. Rheumatol Int (2010) 0.76
Radiological features of experimental staphylococcal septic arthritis by micro computed tomography scan. PLoS One (2017) 0.75
Inflammatory mechanisms in tendinopathy - towards translation. Nat Rev Rheumatol (2017) 0.75
Effects of Almond- and Olive Oil-Based Docosahexaenoic- and Vitamin E-Enriched Beverage Dietary Supplementation on Inflammation Associated to Exercise and Age. Nutrients (2016) 0.75
Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity. Sci Rep (2016) 0.75
Ketamine does not inhibit interleukin-6 synthesis in hepatic resections requiring a temporary porto-arterial occlusion (Pringle manoeuvre): a controlled, prospective, randomized, double-blinded study. HPB (Oxford) (2011) 0.75
Interleukin-6 as a marker of inflammation secondary to endotracheal intubation in pediatric patients. Inflammation (2013) 0.75
Acute exposure to 50-Hz magnetic fields increases interleukin-6 in young healthy men. J Clin Immunol (2011) 0.75
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science (1994) 39.60
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med (1995) 21.16
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood (1995) 16.81
Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science (2003) 14.04
Interleukin-6 and the acute phase response. Biochem J (1990) 7.97
Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity (1999) 7.78
Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science (1997) 6.75
Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol (1997) 6.61
Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science (1996) 6.57
SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol (2003) 4.90
Stat proteins and oncogenesis. J Clin Invest (2002) 4.79
TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity (2004) 4.48
Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood (2005) 4.29
Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood (1996) 4.22
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum (2004) 3.92
Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med (2004) 3.63
Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol (2006) 3.45
Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum (2003) 3.29
Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity (2001) 3.27
Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med (1998) 3.20
CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat Med (2006) 3.11
The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J Clin Invest (2005) 2.91
Transcriptional profiling identifies Id2 function in dendritic cell development. Nat Immunol (2003) 2.91
Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science (2003) 2.87
Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res (1996) 2.86
Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J (1994) 2.83
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum (2002) 2.75
A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology (2004) 2.75
Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood (1999) 2.65
Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol (1997) 2.56
Design of effective immunotherapy for human autoimmunity. Nature (2005) 2.48
I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol (1997) 2.47
Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci U S A (1998) 2.37
Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem (2001) 2.30
Haemopoietic receptors and helical cytokines. Immunol Today (1990) 2.15
Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem (2003) 2.05
The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol (1993) 2.01
A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J Biol Chem (1997) 2.00
Viral IL-6-induced cell proliferation and immune evasion of interferon activity. Science (2002) 1.97
Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol (2006) 1.95
Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol (1992) 1.94
Structure of an extracellular gp130 cytokine receptor signaling complex. Science (2001) 1.94
Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood (1998) 1.93
IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle (2005) 1.79
Maintenance of pluripotency in human embryonic stem cells is STAT3 independent. Stem Cells (2004) 1.73
Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol (2003) 1.68
IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci U S A (2005) 1.66
The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med (1996) 1.65
Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol (1993) 1.62
The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta (2002) 1.61
Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum (1999) 1.57
Sympathetic neurons can produce and respond to interleukin 6. Proc Natl Acad Sci U S A (1998) 1.51
Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine (1992) 1.47
Endogenous interleukin-6, but not tumor necrosis factor alpha, contributes to the development of toll-like receptor 4/myeloid differentiation factor 88-mediated acute arthritis in mice. Arthritis Rheum (2005) 1.47
Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum (2006) 1.42
Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol (1994) 1.41
IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol (1998) 1.34
Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood (1998) 1.32
Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol (1998) 1.31
Dynamics of the gp130 cytokine complex: a model for assembly on the cellular membrane. Protein Sci (2005) 1.23
Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice. Am J Pathol (1998) 1.19
Pathological role of IL-6 in the experimental allergic bronchial asthma in mice. Clin Rev Allergy Immunol (2005) 1.16
Involvement of IL-6, apart from its role in immunity, in mediating a chronic response during experimental arthritis. Am J Pathol (2000) 1.14
Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm (1998) 1.14
Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol (1997) 1.13
Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J Exp Med (1997) 1.13
Molecular mechanisms of cytokine receptor activation. Biochim Biophys Acta (2002) 1.13
Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine (1999) 1.13
Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression. Glia (1999) 1.12
Neural activities of IL-6-type cytokines often depend on soluble cytokine receptors. Eur J Neurosci (1999) 1.11
Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells. Proc Natl Acad Sci U S A (2001) 1.10
Liver regeneration induced by a designer human IL-6/sIL-6R fusion protein reverses severe hepatocellular injury. FASEB J (2000) 1.09
Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis Rheum (2006) 1.07
The family of the IL-6-type cytokines: specificity and promiscuity of the receptor complexes. Proteins (1997) 1.04
IL-6 receptor independent stimulation of human gp130 by viral IL-6. J Immunol (2000) 1.03
Protein kinase C activity is rate limiting for shedding of the interleukin-6 receptor. Biochem Biophys Res Commun (1992) 1.01
IL-6 type cytokine receptor complexes: hexamer, tetramer or both? Biol Chem (1999) 1.01
Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells. Mol Biol Cell (2006) 1.00
Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration. Gastroenterology (2000) 0.99
A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine (1998) 0.98
Studies on the structure and regulation of the human hepatic interleukin-6 receptor. Eur J Biochem (1990) 0.96
Constitutive activation of STAT3 is associated with the acquisition of an interleukin 6-independent phenotype by murine plasmacytomas and hybridomas. Blood (2000) 0.95
Involvement of the acute phase protein alpha 1-acid glycoprotein in nonspecific resistance to a lethal gram-negative infection. J Biol Chem (2000) 0.94
Hyper-IL-6 gene therapy reverses fulminant hepatic failure. Mol Ther (2001) 0.91
The IL-6/sIL-6R fusion protein hyper-IL-6 promotes neurite outgrowth and neuron survival in cultured enteric neurons. J Interferon Cytokine Res (1999) 0.89
HHV-8 is present in multiple myeloma patients. Blood (1999) 0.88
Interleukin-6 and the soluble interleukin-6 receptor induce stem cell factor and Flt-3L expression in vivo and in vitro. Exp Hematol (2001) 0.84
Kaposi's sarcoma-associated herpesvirus and multiple myeloma: lack of criteria for causality. Blood (1999) 0.83
IL6 signalling through IL6 receptor and receptor-associated signal transducer, gp130. Res Immunol (1992) 0.83
Towards determining the differentiation program of antigen-presenting dendritic cells by transcriptional profiling. Eur J Cell Biol (2003) 0.82
A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease. Clin Exp Immunol (2006) 0.82
The effect of gp130 stimulation on glutamate-induced excitotoxicity in primary hippocampal neurons. Biochem Biophys Res Commun (2002) 0.79
Progressive and controlled development of mouse dendritic cells from Flt3+CD11b+ progenitors in vitro. J Immunol (2005) 0.79
Constitutive activation of gp130 leads to neuroendocrine differentiation in vitro and in vivo. Prostate (2005) 0.78
Molecular biology and immunology of interleukin-6. Res Immunol (1992) 0.76
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta (2011) 5.72
TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity (2004) 4.48
Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell (2011) 4.12
The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood (2003) 3.51
CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat Med (2006) 3.11
The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J Clin Invest (2005) 2.91
Transcriptional profiling identifies Id2 function in dendritic cell development. Nat Immunol (2003) 2.91
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest (2011) 2.83
Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology (2009) 2.48
ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol (2011) 2.19
The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol (2004) 2.19
IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res (2005) 2.17
Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism. Nat Immunol (2006) 2.05
Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem (2003) 2.05
Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood (2007) 1.92
Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit Care Med (2011) 1.87
Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J Exp Med (2010) 1.80
Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J Immunol (2007) 1.78
Maintenance of pluripotency in human embryonic stem cells is STAT3 independent. Stem Cells (2004) 1.73
Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J Clin Invest (2003) 1.69
Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol (2003) 1.68
G protein-coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. J Immunol (2009) 1.65
The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J Clin Invest (2005) 1.63
Differentially regulated GPVI ectodomain shedding by multiple platelet-expressed proteinases. Blood (2010) 1.56
The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochim Biophys Acta (2002) 1.53
IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol (2008) 1.48
L1 is sequentially processed by two differently activated metalloproteases and presenilin/gamma-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth. Mol Cell Biol (2005) 1.47
IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest (2011) 1.46
VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J Exp Med (2010) 1.45
A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat Immunol (2010) 1.44
In vivo evidence suggesting reciprocal renal hypoxia-inducible factor-1 upregulation and signal transducer and activator of transcription 3 activation in response to hypoxic and non-hypoxic stimuli. Clin Exp Pharmacol Physiol (2013) 1.41
IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3. J Immunol (2010) 1.39
Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev (2012) 1.38
A key role for gp130 expressed on peripheral sensory nerves in pathological pain. J Neurosci (2009) 1.37
Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood (2007) 1.37
Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. J Immunol (2010) 1.36
The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol (2010) 1.35
Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol (2009) 1.35
IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res (2010) 1.31
Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding. J Biol Chem (2011) 1.29
Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol (2011) 1.29
Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem (2011) 1.29
Interleukin-6 trans-signaling in inflammatory bowel disease. Cytokine Growth Factor Rev (2006) 1.29
IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality. J Clin Invest (2013) 1.28
Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells. J Biol Chem (2006) 1.27
Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages. J Clin Invest (2011) 1.25
The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. J Clin Invest (2008) 1.24
Dynamics of the gp130 cytokine complex: a model for assembly on the cellular membrane. Protein Sci (2005) 1.23
Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages. Gastroenterology (2011) 1.20
IL6/sIL6R complex contributes to emergency granulopoietic responses in G-CSF- and GM-CSF-deficient mice. Blood (2007) 1.20
Inhibition of T cell apoptosis in the aqueous humor of patients with uveitis by IL-6/soluble IL-6 receptor trans-signaling. J Immunol (2004) 1.17
Opposing roles of gp130-mediated STAT-3 and ERK-1/ 2 signaling in liver progenitor cell migration and proliferation. Hepatology (2007) 1.15
HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood (2012) 1.14
Interleukin-6 in sepsis and capillary leakage syndrome. J Interferon Cytokine Res (2011) 1.14
Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor. J Virol (2009) 1.14
Delivery of hyper-interleukin-6 to the injured spinal cord increases neutrophil and macrophage infiltration and inhibits axonal growth. J Comp Neurol (2002) 1.11
Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain. J Neurosci (2014) 1.10
Hitting a complex target: an update on interleukin-6 trans-signalling. Expert Opin Ther Targets (2012) 1.10
The transcription factor NFATc2 controls IL-6-dependent T cell activation in experimental colitis. J Exp Med (2008) 1.10
Ligand/receptor signaling threshold (LIST) model accounts for gp130-mediated embryonic stem cell self-renewal responses to LIF and HIL-6. Stem Cells (2002) 1.09
Elastin-like polypeptides revolutionize recombinant protein expression and their biomedical application. Trends Biotechnol (2009) 1.08
Activation of interleukin-6-induced glycoprotein 130/signal transducer and activator of transcription 3 pathway in mesenchymal stem cells enhances hepatic differentiation, proliferation, and liver regeneration. Liver Transpl (2010) 1.08
Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis Rheum (2006) 1.07
ADAM17-mediated shedding of the IL6R induces cleavage of the membrane stub by gamma-secretase. Biochim Biophys Acta (2009) 1.07
Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis. EMBO Mol Med (2012) 1.07
The substrate degradome of meprin metalloproteases reveals an unexpected proteolytic link between meprin β and ADAM10. Cell Mol Life Sci (2012) 1.05
Role of interleukin-6 for LV remodeling and survival after experimental myocardial infarction. FASEB J (2003) 1.05
Signaling of human ciliary neurotrophic factor (CNTF) revisited. The interleukin-6 receptor can serve as an alpha-receptor for CTNF. J Biol Chem (2003) 1.04
Sleep enhances IL-6 trans-signaling in humans. FASEB J (2006) 1.03
TLR ligand-induced podosome disassembly in dendritic cells is ADAM17 dependent. J Cell Biol (2008) 1.02
The interleukin-6 cytokine system regulates epidermal permeability barrier homeostasis. J Invest Dermatol (2004) 1.01
Genetic manipulations utilizing albumin and alpha-fetoprotein promoter/enhancers affect both hepatocytes and oval cells. Hepatology (2004) 1.01
Interleukin-6 and neural stem cells: more than gliogenesis. Mol Biol Cell (2008) 1.01
An interleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-27 cytokine subunit p28 (IL-30) via a gp130 protein receptor homodimer. J Biol Chem (2012) 1.01
Retracted Natural soluble interleukin-15Ralpha is generated by cleavage that involves the tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17). J Biol Chem (2004) 1.01
Ataxin-10, the spinocerebellar ataxia type 10 neurodegenerative disorder protein, is essential for survival of cerebellar neurons. J Biol Chem (2004) 1.00
Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells. Mol Biol Cell (2006) 1.00
ELPylated anti-human TNF therapeutic single-domain antibodies for prevention of lethal septic shock. Plant Biotechnol J (2011) 0.98
Increased inflammation and lethality of Dusp1-/- mice in polymicrobial peritonitis models. Immunology (2010) 0.98
No inhibition of IL-27 signaling by soluble gp130. Biochem Biophys Res Commun (2005) 0.98
Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration. J Autoimmun (2009) 0.98
N-linked glycosylation is essential for the stability but not the signaling function of the interleukin-6 signal transducer glycoprotein 130. J Biol Chem (2009) 0.98
gp130 dimerization in the absence of ligand: preformed cytokine receptor complexes. Biochem Biophys Res Commun (2006) 0.97
Role of IL-6 trans-signaling in CCl₄induced liver damage. Biochim Biophys Acta (2010) 0.97
Soluble tumor necrosis factor (TNF) receptor-1 induces apoptosis via reverse TNF signaling and autocrine transforming growth factor-beta1. FASEB J (2004) 0.97
Transcription factor NFATc2 controls the emergence of colon cancer associated with IL-6-dependent colitis. Cancer Res (2012) 0.97
IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling. J Immunol (2012) 0.96
Local blockade of IL-6R signaling induces lung CD4+ T cell apoptosis in a murine model of asthma via regulatory T cells. Int Immunol (2007) 0.96
IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier. J Neuroimmunol (2008) 0.93
Forced homo- and heterodimerization of all gp130-type receptor complexes leads to constitutive ligand-independent signaling and cytokine-independent growth. Mol Biol Cell (2010) 0.93
Interleukin-6: a villain in the drama of pancreatic cancer development and progression. Hepatobiliary Pancreat Dis Int (2014) 0.93
Differential expression of CD126 and CD130 mediates different STAT-3 phosphorylation in CD4+CD25- and CD25high regulatory T cells. Int Immunol (2006) 0.92
"Activated" STAT proteins: a paradoxical consequence of inhibited JAK-STAT signaling in cytomegalovirus-infected cells. J Immunol (2013) 0.92
Constitutively active mutant gp130 receptor protein from inflammatory hepatocellular adenoma is inhibited by an anti-gp130 antibody that specifically neutralizes interleukin 11 signaling. J Biol Chem (2012) 0.91
Novel regulatory mechanisms for generation of the soluble leptin receptor: implications for leptin action. PLoS One (2012) 0.91
Viral Interleukin-6: Structure, pathophysiology and strategies of neutralization. Eur J Cell Biol (2010) 0.91
Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130. J Biol Chem (2008) 0.91